The lactogenic hormones prolactin (PRL) and placental lactogen circulate in human fetal plasma during mid and late gestation. T o explore potential roles for the lactogens in fetal development, we examined the cellular distribution and changes in expression of PRL receptors (PRLRs) during ontogeny, and the metabolic effects of PRL signalling and PRLR dysregulation. PRLRs are expressed in diverse tissues of the human fetus by 7.5 weeks of gestation. In fetal bone, adrenal gland and lung, the receptor is expressed first in mesenchymal cells and subsequently in maturing chondrocytes, adrenocortical cells and bronchiolar epithelial cells. That the lactogens play roles in fetal chondrogenesis is suggested by studies in PRLR-deficient mice, which show a delayed ossification of the calvarium. In the central nervous system, the PRLR is detected initially in periventricular neuroepithelium and later in mature neurons of the hypothalamus and olfactory bulb. Finally, in the pancreas, the PRLR is detected first in exocrine tissue and ductal epithelium. Later in gestation and in the postnatal period, PRLRs predominate in pancreatic p-cells. The lactogens regulate p-cell proliferation and insulin production in pancreatic islets, and the insulin secretory response to glucose is blunted in PRLR-deficient mice. These observations suggest roles for the lactogens in pancreatic development and function during pregnancy and postnatal life.
Introduction
The course of human fetal development reveals the potential for rapid and remarkable transformations in tissue composition, cellular organization and biological function. Early gestation is a time of tissue differentiation and organ development. Mid and late gestation are characterized by tissue growth, nutrient storage, and the maturation of organ structure and function critical for independent life after birth.
The metabolic adaptations of the fetus are shaped by complex and dramatic changes in intermediary metabolism in the mother (reviewed in [1, 2] ). In early and mid gestation, maternal hyperphagia induces weight gain, centripetal fat deposition, an increase in lean body mass, a rise in serum leptin and insulin concentrations. Tissue sensitivity to insulin is normal or increased, and the evolving glucose consumption of the placenta and the developing fetus predispose the mother to fasting hypoglycaemia. In the latter half of pregnancy, the sensitivity of maternal tissues to insulin declines. Maternal utilization of glucose falls, despite striking increases in insulin production and glucose-stimulated insulin secretion. The resistance to insulin promotes lipolysis and fasting ketonaemia as well as post-prandial hyperglycaemia, sparing fuels for transport to the fetus. The transplacental delivery of nutrients stimulates a rise in fetal insulin, which promotes fetal growth and the deposition of fat and liver glycogen.
The development of maternal insulin resistance coincides with striking increases in the serum concentrations of the lactogenic hormones prolactin (PRL) and placental lactogen (PL), and of the somatogenic hormone human placental growth hormone (hGH-V) (Figure 1) . The lactogens and somatogens reduce insulin sensitivity in adipocytes and skeletal muscle cells , and stimulate P-cell replication, insulin gene transcription and glucose-dependent insulin secretion in pancreatic islets, producing the insulin resistance and hyperinsulinaemia of late pregnancy [6-lo] . Although lactogenic and somatogenic hormones circulate in fetal as well as maternal plasma, their roles in fetal metabolism remain obscure. Clues regarding these roles may be provided by the patterns of hormone secretion during embryonic and fetal development (reviewed in [l 13). PRL, PL and pituitary hGH (hGH-N) are detected in the coelomic and amniotic fluids as early as 6-8 weeks of gestation. The concentrations of PRL and hGH-N in the amniotic fluid peak at mid gestation, while amniotic fluid PL levels rise to a maximum at 34-36 weeks and then decline prior to term. Circulating levels of hGH-N in the human fetus, as revealed by peri-umbilical blood sampling, decline from a mean of 36 ng/ml at mid gestation to a mean of 20 ng/ml at term. The concentration of human PL, on the other hand, rises 5-6 fold (from 5 to 25-30 ng/ml) during the latter half of gestation, and the fetal serum PRL concentration increases from 20 ng/ml at 28 weeks to 150-300 ng/ml at term. In contrast with hGH-N, hGH-V is not detected in the fetal circulation ( Figure 1 ).
Ontogenesis of PRL receptors (PRLRs)
What roles do these ontogenic changes in hormone expression play in tissue differentiation in early and mid gestation, and in the metabolic and hormonal changes of late fetal development ? T o explore potential functions of the lactogenic hormones, my colleagues and I have analysed the cellular distribution and changes in expression of PRLRs during embryonic, fetal and perinatal development [12-151. The hPRLR binds hPRL, hPL and hGH-N with high affinity ( K , 0.0462.6nM). hPL also binds with very low affinity (K, 770nM) to the hGH receptor [ll] .
Since the concentration of hPL in the fetus never approaches the levels required for interaction with the G H receptor, it is likely that the biological actions of hPL are mediated through binding to the hPRL receptor rather than to the hGH receptor.
In human abortuses, hPL binding activity and mRNA encoding the PRLR are expressed in diverse tissues, including the liver, small intestine, adrenal gland, heart, lung, pancreas, thymus, kidney, brain, testis and skeletal muscle. In early gestation (7.5-10 weeks), PRLR immunoreactivity is detected in tissues derived from embryonic mesoderm, including the peri-adrenal and peri-nephric mesenchyme, the pulmonary and duodenal mesenchyme, skeletal and cardiac myocytes, the mesenchymal pre-cartilage and maturing chondrocytes of the endochondral craniofacial and long bones, vertebrae and ribs. Subsequently there are striking changes in the cellular distribution and magnitude of expression of PRLRs in a number of tissues. In the fetal adrenal gland, the initial mesenchymal expression is succeeded (by 14 weeks of gestation) by the emergence of PRLR immunoreactivity in deeper fetal cortical cell layers. In the fetal kidney and lung, the invagination of cortical mesenchyme is accompanied by progressive receptor immunoreactivity in renal tubular and bronchial airway epithelial cells. In the renal tubules and collecting ducts, the PRLR is expressed primarily on luminal surfaces, consistent with the effects of lactogenic hormones on tubular fluid and electrolyte transport in postnatal animals. In the pulmonary airways, the PRLR is expressed initially in basal epithelial cells and subsequently in surface epithelial cells lining the bronchiolar lumen. In the pancreas, the PRLR is detected in acinar cells and ducts in early gestation; in late gestation and in the postnatal period, however, the PRLR is expressed predominantly in pancreatic islets, co-localizing with insulin.
The rat olfactory system provides a unique template for exploring changes in the cellular distribution of PRLRs during embryonic, fetal and postnatal development [ 141. On embryonic days 12.5-14.5, PRLR immunoreactivity is detected in a patchy distribution in the mesenchyme of the medial nasal process and in the epithelial lining of the olfactory pit. Receptor expression in the olfactory epithelium increases between embryonic days 14.5 and 18, with immunopositive cells in the anteroventral portion of the organ abutting immunonegative cells situated posterodorsally. The olfactory bulb is receptornegative until embryonic day 18. Bulbar receptors are initially expressed in the periventricular neuroepithelium, a germinal matrix that populates the developing organ with neurons. By embryonic day 20.5, there is intense immunoreactivity in the mitral cell layer of the ventral olfactory bulb, with lesser staining of the neuroepithelium and the internal granular layers. By 5 days after birth, the expression of PRLRs in the olfactory bulb is accompanied by the emergence of PRLR mRNA in the neuronal cell bodies of the anterior olfactory nucleus and piriform cortex. With time, the levels of PRLR expression in the olfactory bulb decline markedly, and there is little or no PRLR mRNA in the olfactory bulb of the adult rat. Thus the ontogenesis of PRLRs in the olfactory system is fluid and dynamic, with fluctuations in the distribution and magnitude of expression among tissues, and discontinuous, topographical and changing cellular distributions of receptors within a single tissue.
Biological functions of lactogenic hormones in the fetus
It is unclear whether changes in the expression or cellular distribution of lactogenic receptors within a given organ are a cause or a consequence of changes in that organ's cellular structure or function. Since a human model of total lactogen (PRL, P L and GH-N) deficiency or of lactogen resistance is lacking, the roles of PRL and P L in human tissue differentiation and fetal growth remain unclear. However, the generation of mice with a targeted deletion of the PRLR [16] provides a novel experimental model that may shed light on the roles of the lactogens in fetal and perinatal development. The PRLR-deficient mice are viable, indicating that the early murine embryo is capable of cellular differentiation and proliferation in the absence of PRL signalling. However, the PRLR-deficient mouse embryos show delayed ossification of the calvaria, suggesting that lactogens play roles in fetal osteoblast function and bone development [17] . Such findings concord with the distribution of PRLRs in maturing chondrocytes of developing bones [ 13-1 51. The linear growth of the mice has not yet been assessed, but recent findings have revealed small reductions in body weight and abdominal fat content after 12-16 weeks of age [18] . A role for lactogens in fetal growth had been suggested previously by studies showing that hPL stimulates amino acid uptake, DNA synthesis and insulin-like growth factor-I production in human fetal myoblasts and fibroblasts [ 1 11 .
Despite years of study, the roles of the lactogens in intermediary metabolism remain unclear. As noted above, lactogenic hormones stimulate 8-cell replication, insulin gene transcription and glucose-dependent insulin secretion in pancreatic islets from neonatal rats and mice and from human adults [6-lo] . These observations suggest a role for lactogens in islet development and function.
T o clarify the roles of the lactogens in islet growth and maturation, my colleagues and I generated a stable line of rat insulinoma (INS-1) cells that express rat P L I1 constitutively in culture [lo] (Figure 2 ). Rat P L I1 is the major circulating lactogen in the fetal rat in late gestation. Constitutive expression of rat P L I1 led to /?-cell aggregation and proliferation, cellular glucose uptake, and the induction of preproinsulin and G L U T 2 mRNAs. Similar findings were noted in subsequent studies in which mouse P L I1 was overexpressed in the pancreatic islets of transgenic mice in vivo [19] . Lactogen induction of 8-cell The insulin secretory response to glucose is blunted in isolated islets from PRLR-deficient male mice minutes aggregation coupled with localized p-cell growth may contribute to the expansion of islet mass that occurs during the perinatal period. The induction of insulin and G L U T 2 mRNAs provides a mechanism by which the lactogens may increase fetal insulin production and enhance the sensitivity of the pancreas to glucose. Support for a role for the lactogens in insulin production was provided by our recent studies of carbohydrate metabolism in adult PRLR-deficient mice. The insulin secretory response to glucose is blunted in male PRLR-deficient mice in vivo and in isolated pancreatic islets from PRLRdeficient mice in oitro (Figure 3 ). It is currently unclear whether the defect in glucose-dependent insulin secretion in PRLR-deficient mice reflects a decrease in the size, number and/or function of individual islets, and the effects of PRLR deficiency on fetal islet development and perinatal insulin production are as yet unknown.
Conclusion
In summary, the increases in circulating lactogen concentrations in mid to late gestation, the induction of lactogen receptors in maturing fetal tissues, and the biological effects of lactogen 41 resistance in the PRLR-deficient mouse suggest novel roles for the lactogenic hormones in fetal and perinatal development.
